Tertiary prevention of HBV-related HCC in Asia

被引：1
作者：
Wong G.L.-H. [1 ,2 ]
Chong C.-N. [1 ,3 ]
Wong V.W.-S. [1 ,2 ]
机构：
[1] Institute of Digestive Disease, Chinese University of Hong Kong, Hong Kong
[2] Department of Medicine and Therapeutics, Chinese University of Hong Kong, 9/F, Prince of Wales Hospital, Shatin
[3] Department of Surgery, Chinese University of Hong Kong, Hong Kong
来源：
Current Hepatitis Reports | 2013年 / 12卷 / 3期
关键词：
Cirrhosis; Entecavir; HBV DNA; Hepatitis B; Hepatocellular carcinoma; Interferon; Lamivudine; Sirolimus; Sorafenib; Tenofovir;
D O I：
10.1007/s11901-013-0171-9
中图分类号：
学科分类号：
摘要：
Chronic hepatitis B is the leading cause of hepatocellular carcinoma (HCC) in Asia. Despite liver resection or local ablation therapy, up to 70 % of patients will have HCC recurrence. While early HCC recurrence within 2 years of index treatment is mainly associated with tumor characteristics such as vascular invasion and tumor number, late recurrence arises due to field effect and is associated with high hepatitis B virus DNA level and hepatic necroinflammation. Although current data suggest that antiviral therapy can reduce the risk of cirrhosis and incident HCC, its role in preventing HCC recurrence after curative treatment remains controversial. In recent years, knowledge on the signaling pathways of HCC has led to exciting development in targeted therapy, with sorafenib being the first to be registered for the treatment of advanced HCC. Further studies are needed to clarify the role of targeted therapy in the adjuvant setting to prevent HCC recurrence. © 2013 Springer Science+Business Media New York.
引用
收藏
页码：157 / 164
页数：7
相关论文
共 79 条
[1]  
Wong V.W., Chan H.L., Prevention of hepatocellular carcinoma: A concise review of contemporary issues, Ann Hepatol., 11, pp. 284-293, (2012)
[2]  
Chang M.H., You S.L., Chen C.J., Et al., Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: A 20-year follow-up study, J Natl Cancer Inst., 101, pp. 1348-1355, (2009)
[3]  
Liaw Y.F., Sung J.J., Chow W.C., Et al., Lamivudine for patients with chronic hepatitis B and advanced liver disease, N Engl J Med, 351, pp. 1521-1531, (2004)
[4]  
Sung J.J., Tsoi K.K., Wong V.W., Et al., Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma, Aliment Pharmacol Ther, 28, pp. 1067-1077, (2008)
[5]  
Wong G.L., Chan H.L., Chan H.L., Et al., Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis, Hepatology, (2013)
[6]  
Wong G.L., Wong V.W., Tan G.M., Et al., Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis, Liver Int, 28, pp. 79-87, (2008)
[7]  
Belghiti J., Panis Y., Farges O., Et al., Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis, Ann Surg, 214, pp. 114-117, (1991)
[8]  
Wu J.C., Huang Y.H., Chau G.Y., Et al., Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma, J Hepatol, 51, pp. 890-897, (2009)
[9]  
Figueras J., Jaurrieta E., Valls C., Et al., Resection or transplantation for hepatocellular carcinoma in cirrhotic patients: Outcomes based on indicated treatment strategy, J Am Coll Surg, 190, pp. 580-587, (2000)
[10]  
Facciuto M.E., Rochon C., Pandey M., Et al., Surgical dilemma: Liver resection or liver transplantation for hepatocellular carcinoma and cirrhosis. Intention-to-treat analysis in patients within and out with Milan criteria, HPB (Oxford), 11, pp. 398-404, (2009)
12345678